Search Results 971-980 of 16351 for monoclonal antibody

  1. Publications - Mark A. Edgar, M.D. - Mayo Clinic

    Intraparenchymal and intratumoral interstitial infusion of anti-glioma monoclonal antibody 8H9. Neurosurgery. 2008 Dec; 63 (6):1166-74; discussion 1174. View ...

  2. Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial) - Mayo Clinic

    ... monoclonal antibody TTR amyloid depleter agent within 12 months. Contraindication to or inability to undergo CMR testing; Presence of condition known to ...

  3. A Study to Evaluate the Effectiveness and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects with Mycosis Fungoides - Mayo Clinic

    Antibody-directed or immunoglobulin-based immune therapy or other monoclonal antibody therapies within 8 weeks prior to Screening;; Previous chronic (more ...

  4. A Study to Investigate Intravenous Tocilizumab in Patients with Moderate-to-Severe COVID-19 Pneumonia (enrolling by invitation only) - Mayo Clinic

    Known severe allergic reactions to TCZ or other monoclonal antibodies;; Active TB infection;; Suspected active bacterial, fungal, viral, or other infection ...

  5. Clinical trials - Oncology (Medical)

    The purpose of this study is to determine the cellular and mechanistic basis of bone marrow hematopoietic dysfunction in untreated Monoclonal B Cell ...

  6. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab - Mayo Clinic

    History of severe hypersensitivity reaction to any monoclonal antibody. Women of Childbearing Potential (WOCBP) who are pregnant or breastfeeding. Women ...

  7. A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma - Mayo Clinic

    Monoclonal antibody (ies). At least 28 days since the last dose of monoclonal antibody prior to first dose of tazemetostat. Immunotherapy (e.g., tumor vaccine).

  8. Lowering Rejection Risk in Organ Transplants - Mayo Clinic

    Stegall, M.D., Transplantation Surgery, Mayo Clinic: About 80 percent of people who have had a previous transplant have antibodies against other tissue types.

  9. MS or not MS? Mayo Clinic Neuroimmunology Lab answers the question

    The AQP4 antibody, discovered at Mayo Clinic in 2004, was the first biomarker associated with inflammatory demyelinating diseases that could be used to ...

  10. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

    Participation eligibility · Subjects with any history of hypersensitivity to any monoclonal antibody (including mepolizumab). · Subjects with current malignancy ...